An HRS meeting recap, Impella failure, sacubitril/valsartan, the purpose of trials, and a major breakthrough in evidence generation are the topics discussed by John Mandrola, MD in this week's podcast.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit: https://www.medscape.com/twic

I. HRS Meeting Recap

II. Impella in VT ablation

- First-in-human Experience with Impella 5.0/5.5 for High-Risk Patients with Advanced Heart Failure Undergoing VT Ablationhttps://www.jacc.org/doi/10.1016/j.jacc.2023.05.012

III. Sacubitril/Valsartan

ARNI Bests ARB to Reduce NT-proBNP in Stabilized Preserved-EF HF

https://www.medscape.com/viewarticle/992461

- Angiotensin-Neprilysin Inhibition in Patients With Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure

https://www.jacc.org/doi/10.1016/j.jacc.2023.04.019

- Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction

https://www.nejm.org/doi/full/10.1056/nejmoa1908655

- Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF

https://doi.org/10.1093/eurheartj/ehad344

- Bogdan Tweet

https://twitter.com/bogdienache/status/1660356776204595201?s=20

IV. Big Change in Reporting of Medical Evidence – Elan Trial

- Early versus Later Anticoagulation for Stroke with Atrial Fibrillationhttps://www.nejm.org/doi/full/10.1056/NEJMoa2303048

- Early versus Late initiation of direct oral Anticoagulants in post-ischaemic stroke patients with atrial fibrillatioN (ELAN): Protocol for an international, multicentre, randomised-controlled, two-arm, open, assessor-blinded trial https://doi.org/10.1177/23969873221106043

May 26 2023 This Week in Cardiology